Six Chinese Innovative Biopharma Companies Secure Over RMB 100 Million in December Funding Rounds

　　【Pharmaceutical Network Industry DynamicsAccording to the review, as of December 30, at least 8 Chinese companies dedicated to innovative drug research and development announced the completion of a new round of financing in December, among which at least 6 companies raised over 100 million yuan.
 

Among them, AusperBio announced on December 27 the completion of a $73 million Series B financing round. The proceeds from this round will primarily be used to advance the China and international clinical trials of its core small nucleic acid innovative drug, AHB-137, as well as preparations for early commercialization. Additionally, the funds will support the expansion of the company’s new R&D pipeline and the ongoing development and growth of the team.
 

Data shows that AusperBio is an innovative biopharmaceutical company with a global presence and in the clinical stage. It is committed to transforming hepatitis B curative therapies and oligonucleotide technology innovation. Relying on its proprietary Med-Oligo™ ASO platform and highly efficient targeted delivery technology, the company focuses on revolutionary ASO therapies applied in areas such as viral infections, metabolic diseases, genetic disorders, and immune diseases, aiming to improve patients' lives.
 

Eli Radiopharma Announces Completion of Angel Round Financing Worth Hundreds of Millions of RMB on December 24The funds raised will be used to build Eli Radiopharma's innovative radiopharmaceuticals platform, further enhancing the company’s R&D capabilities. Additionally, the funding will help accelerate the progress of the company’s clinical projects and expand the team size, comprehensively advancing the overall strategic development process of Eli Radiopharma.
 

Data shows that Eli Radiopharma is an innovative radiopharmaceutical company dedicated to targeted radiotherapy and integrated diagnosis and treatment. The company focuses on the two fields of oncology and neuroscience.
 

Angitia announced on December 13 the completion of a $120 million Series C financing round. The proceeds from this round will be used to support Angitia's innovative drug pipeline, focusing on developing differentiated and innovative treatment solutions for severe diseases in the bones, joints, and muscles.
 

Data shows that Angitia is an innovative drug research and development company focusing on severe diseases in the fields of bones, joints, and muscles. Currently, it has three biologic macromolecule candidate drugs in clinical research stages, aiming to treat osteoporosis, osteogenesis imperfecta (OI), and spinal fusion.
 

Farber New Heaven announced on December 9 the completion of its A2 round of financing worth hundreds of millions, which will mainly be used for the research and development of Farber New Heaven's existing pipeline and the construction of a radiopharmaceutical industrialization base. Data shows that Farber New Heaven is a research and development enterprise focusing on molecular imaging diagnostics and radiopharmaceutical treatments.
 

Wuhan Kaidewei Biotechnology Co., Ltd. announced on December 5 the completion of a nearly 200-million-yuan Series B financing round. The funds will be used for clinical development and market expansion of the company’s various products in the field of gynecological oncology diagnosis and treatment.
 

Data shows that Wuhan Kaidewei Biotechnology Co., Ltd. has deeply integrated into the entire process of screening, diagnosis, prevention, and treatment of gynecological tumors. Two of the company's self-developed in vitro diagnostic kits have been approved for entry into the National Medical Products Administration (NMPA) innovative medical device review fast track for two consecutive years. These kits are expected to facilitate rapid screening and precise diagnosis and treatment of gynecological tumors such as endometrial cancer and cervical cancer, as well as their precancerous lesions. The company’s independently developed novel recombinant oncolytic adenovirus product has been approved for Phase I clinical trials.
 

AFFINITY announced on December 2 that its parent company, Yafei (Shanghai) Biomedical Technology Co., Ltd., has completed the B2 round of financing. The investment in this round exceeded 400 million RMB. The injection of funds from this round will provide strong momentum for AFFINITY in the global clinical research process of innovative drugs, accelerating the research and development of the company's technology platform and drugs to meet the urgent clinical needs in the field of cancer treatment.
 

Data shows that AFFINITY is an innovative anti-cancer drug company. It has built a multispecific smart conjugate drug technology platform that is only activated in the tumor microenvironment, including a tumor microenvironment-activated small molecule conjugate drug, tumor microenvironment-activated antibodies, bispecific drugs, and tumor microenvironment-activated ADC as the core of an integrated R&D innovation system. It has developed more than 20 innovative candidate drugs for the treatment of cancer and other major diseases.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.